Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05753189 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Safety Study for the Treatment of Presbyopia Subjects
A Phase 3 study of Presbyopia and Eye Diseases, sponsored by LENZ Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 362
- Enrollment target
- 20
- Study locations
NCT05753189: Completed Phase 3 study of Presbyopia and Eye Diseases, sponsored by LENZ Therapeutics.
NCT05753189 is a Phase 3 study of Presbyopia and Eye Diseases that has completed, run by LENZ Therapeutics. The registered enrollment target is 362 participants, above the 261-participant average among 38 other Presbyopia trials with a reported enrollment target (39% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05753189, a Phase 3 study of Presbyopia and Eye Diseases, has completed, sponsored by LENZ Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 362 participants
- Enrollment target
- 20
- Study locations
Study Summary
Safety Study of the Long-Term Safety of LNZ101 in Presbyopic Subjects
Primary Outcome
Number and Percentage of Participants with at least one Treatment-Related Treatment-Emergent Adverse Events (TEAE) were collected by systematic assessment and coded using MedDRA.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Aceclidine+Brimonidine combination ophthalmic solution
- DRUG Aceclidine Ophthalmic Solution
Study Locations (20)
California
- Site #303 - Garden Grove
- Site #313 - Glendale
- Site #334 - La Jolla
- Site #322 - Newport Beach
- Site #306 - Petaluma
- Site #337 - Rancho Cordova
- Site #304 - Santa Barbara
Arizona
- Site #302 - Chandler
- Site #320 - Mesa
- Site #321 - Phoenix
- Site #328 - Phoenix
- Site #338 - Scottsdale
- Site #331 - Sun City
Florida
- Site #319 - Crystal River
- Site #309 - Mt. Dora
Alabama
- Site #326 - Dothan
Colorado
- Site #308 - Littleton
Connecticut
- Site #316 - Danbury
Illinois
- Site #317 - Rock Island
Kansas
- Site #301 - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 362 participants |
| Start Date | 2023-02-21 |
| Est. Completion | 2024-02-09 |
| Phase | Phase 3 |
What the finished NCT05753189 record still lists
NCT05753189 is an interventional study that assigns participants to a tested intervention. The registered 362 participants enrollment target is mid-sized for trials with a published cap, above the 261-participant average among 38 other Presbyopia trials with a reported enrollment target (39% higher).
The record links to 4 conditions, with Presbyopia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05753189 names 20 study sites across 8 states, led by California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT05753189 about?
NCT05753189 is a clinical study titled "Phase 3 Safety Study for the Treatment of Presbyopia Subjects". Safety Study of the Long-Term Safety of LNZ101 in Presbyopic Subjects
What is the current status of trial NCT05753189?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 362 participants. The study started on 2023-02-21. Estimated completion is 2024-02-09.
What conditions does trial NCT05753189 study?
This clinical trial studies the following conditions: Presbyopia, Eye Diseases, Near Vision, Miosis.
What interventions are being tested in trial NCT05753189?
The interventions under investigation include: Placebo (DRUG), Aceclidine+Brimonidine combination ophthalmic solution (DRUG), Aceclidine Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT05753189?
This trial is sponsored by LENZ Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05753189 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Presbyopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05753189's enrollment target sits among peer trials
362 6th of 38 higher than 33 of 38 other Presbyopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Presbyopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase III Presbyopia Correction Using the VIS Opti-K™ System
RECRUITING · Phase 3
-
Safety & Efficacy of Pilocarpine Eye Solutions for Temporary Improvement of Near Vision in Presbyopic Adults
COMPLETED · Phase 3
-
Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
COMPLETED · Phase 3
-
Safety & Efficacy of Pilocarpine Ophthalmic Spray for Temporary Improvement of Near Vision in Presbyopic Adults
COMPLETED · Phase 3
-
An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2)
COMPLETED · Phase 3
-
Post Market Clinical Evaluation of Clareon PanOptix Pro and Clareon PanOptix Pro Toric IOLs
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04988555 · 362 participants · Phase 1
A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation
- NCT05536141 · 362 participants · Phase 1
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- NCT06534983 · 362 participants · Phase 2
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
- NCT06472245 · 363 participants · Phase 3
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI